Icosavax is an American biotechnology company based in Seattle, Washington.
History
Icosavax was founded in 2017 to advance virus-like particle (VLP) technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.[1]
Activities
Icosavax is developing products for SARS-CoV-2, RSV and human metapneumovirus (hMPV).
Funding
Icosavax has received COVID-19-related funding from Good Ventures on a recommendation from Open Philanthropy.[2]
External links
Corporate profile. Icosavax. Retrieved March 12, 2023, from http://archive.today/2023.03.12-054948/https://ir.icosavax.com/ ↩︎
Grants - COVID. Open Philanthropy. Retrieved July 25, 2023, from https://web.archive.org/web/20230725225518/https://www.openphilanthropy.org/grants/?q=COVID&sort=a-z&items=100&view-list=true#categories ↩︎
